Literature DB >> 26392439

Leukaemia cutis after starting bendamustine: cause or coincidence?

Sagger Mawri1, Shahzaib Nabi1, Bassel Jallad2, Joseph Won3.   

Abstract

A 55-year-old man with a history of chronic lymphocytic leukaemia presented with diffuse skin lesions that began 1 week after starting a new chemotherapy regimen with bendamustine and rituximab. The lesions appeared as erythematous papules that were neither itchy nor tender, and did not blanch with pressure. Initially, they began on his scalp and flanks and, over the next few days, spread diffusely throughout his body, becoming darker in colour. Skin biopsy showed atypical clonal B-cell proliferation in a perivascular, periadnexal and dermal band-like distribution, which was further characterised by immunohistochemical evaluation. These findings were suggestive of leukaemia cutis and consistent with the patient's chronic lymphocytic leukaemia, which was previously confirmed by bone marrow biopsy. The bendamustine was stopped and the patient's chemotherapy regimen was switched to fludarabine, cyclophosphamide and rituximab. Shortly thereafter, the leukaemia cutis regressed significantly. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392439      PMCID: PMC4577706          DOI: 10.1136/bcr-2014-209025

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: an underemphasized clinical problem.

Authors:  Christopher B Weldon; Bernard M Jaffe; Marc J Kahn
Journal:  Ann Surg Oncol       Date:  2002-10       Impact factor: 5.344

2.  Effective treatment of leukemia cutis with combination of rituximab, cladribine, and cyclophosphamide in patient with B-cell chronic lymphocytic leukemia.

Authors:  Aleksandra Batycka-Baran; Wojciech Baran; Justyna Dzietczenia; Grzegorz Mazur
Journal:  Ann Hematol       Date:  2010-10-27       Impact factor: 3.673

3.  Therapy-related leukemia cutis after adjuvant chemotherapy in a breast cancer patient.

Authors:  Haur Yueh Lee; Heng Joo Ng; Pek Choo Adele Wong; Shiu Ming Pang
Journal:  Acta Derm Venereol       Date:  2010-11       Impact factor: 4.437

Review 4.  Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012.

Authors:  Megan Ratterman; Kimberly Kruczek; Suela Sulo; Tait D Shanafelt; Neil E Kay; Chadi Nabhan
Journal:  Leuk Res       Date:  2013-09-06       Impact factor: 3.156

5.  Severe cutaneous interface drug eruption associated with bendamustine.

Authors:  Habibollah S Alamdari; Lauren Pinter-Brown; David S Cassarino; Melvin W Chiu
Journal:  Dermatol Online J       Date:  2010-07-15

6.  Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.

Authors:  B Malipatil; P Ganesan; S Sundersingh; T G Sagar
Journal:  Hematol Oncol Stem Cell Ther       Date:  2011

7.  [Therapy-resistant cutaneous infiltrates in chronic lymphocytic leukemia].

Authors:  C Sucker; G Lorenz; G Dölken; M Stockschläder
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

Review 8.  Skin manifestations of adult T-cell leukemia/lymphoma: clinical, cytological and immunological features.

Authors:  Yoshiki Tokura; Yu Sawada; Takatoshi Shimauchi
Journal:  J Dermatol       Date:  2014-01       Impact factor: 4.005

9.  Leukaemia cutis in chronic lymphocytic leukaemia following varicella zoster virus reactivation.

Authors:  G Hapgood; E Mooney; H V Dinh; D Gin; C McLean; S B Ting
Journal:  Intern Med J       Date:  2012-12       Impact factor: 2.048

Review 10.  Skin lesions in chronic lymphocytic leukemia.

Authors:  Ewa Robak; Tadeusz Robak
Journal:  Leuk Lymphoma       Date:  2007-05
View more
  1 in total

Review 1.  Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL).

Authors:  Mahmood B Aldapt; Mohamed Yassin
Journal:  Acta Biomed       Date:  2021-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.